Dr. Saag has received consulting fees and/or honoraria (less than $10,000) and grant support from Amgen. Dr. Kramer has served as a consultant to the FDA in designing, analyzing, and interpreting a study on heart failure associated with tumor necrosis factor inhibitors and has received consulting fees ($10,000) from the FDA. Dr. Kramer has served as a consultant on the Engalitcheff grant awarded to the University of Alabama.
Contribution from the Field
Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs
Article first published online: 28 FEB 2007
Copyright © 2007 by the American College of Rheumatology
Arthritis Care & Research
Volume 57, Issue 2, pages 343–346, 15 March 2007
How to Cite
Curtis, J. R., Martin, C., Saag, K. G., Patkar, N. M., Kramer, J., Shatin, D., Allison, J. and Braun, M. M. (2007), Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs. Arthritis & Rheumatism, 57: 343–346. doi: 10.1002/art.22544
- Issue published online: 28 FEB 2007
- Article first published online: 28 FEB 2007
- Manuscript Accepted: 25 JUL 2006
- Manuscript Received: 7 APR 2006
- FDA Center for Biologics Evaluation and Research. Grant Number: award 223-02-1420 Task Order 1
- Agency for Healthcare Research and Quality. Grant Number: HS-10389
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: K24-AR-052361-01
- NIH. Grant Number: T32-AR-47512-03
- 3Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease [published erratum in Inflamm Bowel Dis 2005;11:705]. Inflamm Bowel Dis 2004; 10: 436–7., , , , , .
- 5UnitedHealthGroup. In: StromB, editor. Pharmacoepidemiology. 4th ed. West Sussex: John Wiley & Sons; 2005., , .
- 7Validity of pharmacoepidemiologic drug and diagnosis data. In: StromBL, editor. Pharmacoepidemiology. 4th ed. West Sussex: John Wiley & Sons; 2005., , .
- 8Opportunistic infections with anti-TNF agents: estimating incidence from pharmacy and physician claims databases. Arthritis Rheum 2005; 52: S349–50., , .
- 9Rates of infection in rheumatoid arthritis [abstract]. Arthritis Rheum 2004; 50: S478–9., , , .
- 10Failure to validate pneumococcal pneumonia diagnoses in the general practice research database [abstract]. Pharmacoepidemiol Drug Saf 2003; 12: S163–4., .